In use product safety assessment report for trastuzumab

A UKMi Product Safety assessment on  trastuzumab products (including the biosimilars) which describes the in-use medication safety considerations resultant from the product’s presentation or other pre-defined characteristics. Potential next steps and mitigation actions are suggested.

The UKMI product safety assessment group would appreciate your views on the usefulness of this assessment. We have devised a short survey which we would appreciate you completing, it should take approximately 10 minutes to complete. Click here – – to complete the survey.

Medicines SafetyNewsTrastuzumabTrastuzumab emtansine